WIPO logo
Celular | Deutsch | English | Español | Français | 日本語 | 한국어 | Русский | 中文 | العربية |
PATENTSCOPE

Pesquisa nas coleções internacionais e nacionais de patentes
World Intellectual Property Organization
Pesquisa
 
Navegação
 
Traduzir
 
Opções
 
Notícias
 
Conectar-se
 
Ajuda
 
Tradução automática
1. (WO2015089389) PRODRUG FOR RELEASE OF CISPLATIN AND CYCLOOXYGENASE INHIBITOR
Dados bibliográficos mais recentes no arquivo da Secretaria Internacional   

№ de pub.:    WO/2015/089389    № do pedido internacional:    PCT/US2014/069997
Data de publicação: 18.06.2015 Data de depósito internacional: 12.12.2014
CIP:
C07F 15/00 (2006.01), A61K 47/48 (2006.01), A61K 31/282 (2006.01), A61P 35/00 (2006.01), A61P 31/00 (2006.01)
Requerentes: UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. [US/US]; Boyd Graduate Studies Research Center Athens, GA 30602-7411 (US)
Inventores: DHAR, Shanta; (US).
PATHAK, Rakesh; (US)
Mandatário: CAMPBELL, Keith, M.; (US)
Dados da prioridade:
61/915,110 12.12.2013 US
61/976,559 08.04.2014 US
Título (EN) PRODRUG FOR RELEASE OF CISPLATIN AND CYCLOOXYGENASE INHIBITOR
(FR) PRODROGUE POUR LIBÉRATION DE CISPLATINE ET D'UN INHIBITEUR DE CYCLOOXYGÉNASE
Resumo: front page image
(EN)Pt(IV) prodrugs include one or more conjugated cyclooxygenase inhibitor. Reduction of Pt(IV) to Pt(II) can result cisplatin and a cyclooxygenase inhibitor. For proof of concept, a Pt(IV) prodrug that can produce cisplatin and aspirin, Platin-A, was synthesized. Platin-A exhibited excellent anticancer and anti-inflammatory properties, which were better than the combination of free formulation of cisplatin and aspirin.
(FR)Les prodrogues au Pt(IV) comprennent un ou plusieurs inhibiteurs de cyclooxygénase conjugués. La réduction du Pt(IV) en Pt(II) peut conduire au cisplatine et à un inhibiteur de cyclooxygénase. Comme preuve du concept, une prodrogue d'un Pt(IV) a été synthétisée, qui peut produire du cisplatine et de l'aspirine, le Platine-A. Le Platine-A a présenté d'excellentes propriétés anticancéreuses et anti-inflammatoires, qui ont été meilleures que l'association de la formulation libre de cisplatine et d'aspirine.
Estados designados: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Língua de publicação: English (EN)
Língua de depósito: English (EN)